Variable | CTP cohort (n=508) | NCCT cohort (n=357) |
Age (years), mean±SD | 64.1±15.3 | 66±15 |
Sex, female | 49.8% (253) | 47% (185) |
BMI, mean±SD | 29.2±6.4 | 29.3±9.5 |
Medical history: | ||
Hypertension | 69.7% (354) | 74.8% (267) |
Dyslipidemia | 33.3% (169) | 37% (132) |
Atrial fibrillation | 28.7% (146) | 41.9% (149) |
Diabetes mellitus | 24.2% (123) | 27% (96) |
Current smoking | 17.1% (87) | 18.7% (66) |
Glucose (mg/dL), mean±SD | 162.5±58.3 | 139±54 |
Clot locations: | ||
ICA terminus | 17.9% (91) | 24.9% (89) |
Extracranial ICA | 16.1% (82) | 9.5% (34) |
M1 MCA | 60.8% (309) | 60.2% (215) |
M2 MCA | 20.9% (106) | 16% (57) |
Stroke etiology: | ||
Cardioembolic | 45.5% (231) | 59.7% (207) |
Large vessel atherosclerosis | 18.3% (93) | 11.2% (39) |
Intracranial atherosclerotic disease | 6.1% (31) | 4.6% (16) |
Dissection | 2.2% (11) | 3.7% (13) |
Other etiology | 3.0% (15) | 2% (7) |
Carotid web | 0.4% (2) | 0.9% (3) |
Undetermined | 19.3% (98) | 17.9% (62) |
Baseline NIHSS score, median (IQR) | 16 (12–20) | 19 (14–23) |
Time last-seen-well to ET (min), median (IQR) | 350 (240–610) | 283 (208–399) |
Intravenous tPA given | 38.6% (196) | 51.3% (183) |
ASPECTS baseline, median (IQR) | 8 (7–9) | 8 (7–9) |
Total core volume-primary (rCBF<30%), mean±SD | 16.7±24.8 | n/a |
Hypoperfusion-primary (Tmax>6.0 s), mean±SD | 157.2±111.9 | n/a |
Mismatch volume-primary, mean±SD | 140.2±110.2 | n/a |
PRE score, mean±SD | 18.6±26.3 | n/a |
Outcomes: | ||
mTICI 0/1 | 2.0% (10) | 4.6% (18) |
mTICI 2a | 3.7% (19) | 9.6% (38) |
mTICI 2b | 38.6% (196) | 46.6% (185) |
mTICI 2c/3 | 55.7% (283) | 38.8% (153) |
90-Day good outcome (mRS 0–2) | 54.9% (279) | 39.2% (140) |
Results are shown as % (n) unless stated otherwise. ASPECTS, Alberta Stroke Program Early CT Score; BMI, body mass index; CTP, CT perfusion, ET, endovascular therapy; ICA, internal carotid artery; MCA, middle cerebral artery; mRS, modified Rankin Scale; mTICI modified Thrombosis in Cerebral Infarction; NCCT, non-contrast CT; NIHSS, National Institutes of Health Stroke Scale; PRE, Pittsburgh Response to Endovascular therapy; rCBF, relative cerebral blood flow; tPA, tissue plasminogen activator.